Industry Veteran Scott Addonizio joins MedAlliance as COO

6 January 2020 – Sirolimus-eluting balloon specialist MedAlliance has announced the appointment of Scott Addonizio as Chief Operating Officer. Scott has an excellent track record and reputation in the global medical device industry, with over 24 years’ experience. This includes expertise in balloon manufacturing, in-depth knowledge of the global coronary, peripheral and AV Fistula marketplace, as well as a solid understanding of the global regulatory environment.

Scott was most recently a Board Director of OrbusNeich Medical, where he was responsible for global operations. He held the titles of Senior Vice President & Chief Operating Officer. Having spent the last 15 years overseas, the majority in mainland China, he has considerable knowledge of key global markets and has familiarized himself with the local language, customs and business culture of those regions. Scott is the primary patent holder for the “Stent Having Dual Helical Design”, which provides the backbone for all OrbusNeich stent platforms. Scott holds a degree in Packaging Engineering from Michigan State University and an MBA in International Business from the University of Miami.

As COO Scott will lead MedAlliance operations including Manufacturing, Regulatory, Clinical and R&D, as well as MA’s logistical organization. He will be based in Irvine, California.

“We are delighted to welcome someone of Scott’s calibre to MedAlliance” commented Chairman and CEO Jeffrey B. Jump. “His inherent knowledge and experience in a rapid growth company will be an important contribution to our continued success”.

“I’m extremely excited to be joining the MedAlliance team at this critical stage in the company’s development” added Scott. “We are on the brink of receiving the first regulatory approvals to facilitate launch of our sirolimus-eluting balloon, as well as further expanding clinical trials and indications. I believe MedAlliance will have a significant impact on addressing several of the key deficiencies that exist in the drug-eluting balloon marketplace today”.

Media Contact:
Richard Kenyon